Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.O)

ALNY.O on Nasdaq

81.42USD
18 Aug 2017
Change (% chg)

$1.14 (+1.42%)
Prev Close
$80.28
Open
$80.29
Day's High
$81.99
Day's Low
$79.79
Volume
574,759
Avg. Vol
967,716
52-wk High
$86.92
52-wk Low
$31.38

ALNY.O

Chart for ALNY.O

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.94
Market Cap(Mil.): $7,468.93
Shares Outstanding(Mil.): 91.73
Dividend: --
Yield (%): --

Financials

  ALNY.O Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -5.12 -- --
ROI: -33.58 2.83 14.89
ROE: -39.86 5.09 16.13

BRIEF-Alnylam Pharmaceuticals reports Q2 adj loss per share $1.07

* Alnylam Pharmaceuticals reports second quarter 2017 financial results and highlights recent period activity

Aug 09 2017

BRIEF-Alnylam Pharmaceuticals and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study

* Alnylam and Sanofi Genzyme report positive results from ongoing phase 2 open-label extension study with investigational RNAI therapeutic Fitusiran in patients with hemophilia A and B with or without inhibitors

Jul 10 2017

BRIEF-Alnylam and Sanofi Genzyme initiate ATLAS Phase 3 program with investigational RNAi therapeutic fitusiran

* Alnylam and Sanofi Genzyme initiate ATLAS phase 3 program with investigational RNAi therapeutic fitusiran

Jul 07 2017

BRIEF-Alnylam Pharmaceuticals reports results for Givosiran

* Alnylam reports new positive clinical results for Givosiran (ALN-AS1), an investigational RNAI therapeutic for the treatment of acute hepatic porphyrias

Jun 26 2017

BRIEF-Alnylam CEO, John Maraganore, named BIO chair for 2017-2018 term

* Alnylam CEO, John Maraganore, named BIO chair for 2017-2018 term

Jun 19 2017

BRIEF-Alnylam expands patent portfolio with allowances from U.S. Patent and Trademark Office

* Alnylam significantly expands patent portfolio with new allowances from United States Patent and Trademark Office Source text for Eikon: Further company coverage:

Jun 12 2017

BRIEF-Alnylam Pharmaceuticals expects to end 2017 with over $1 bln in cash, cash equivalents, fixed income marketable securities

* Company updated its cash guidance for year ending december 31, 2017 - sec filing

Jun 06 2017

BRIEF-FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for prophylaxis of attacks in patients with acute hepatic porphyria

* FDA grants Breakthrough Therapy Designation for Alnylam’S Givosiran for the prophylaxis of attacks in patients with acute hepatic porphyria

May 31 2017

BRIEF-Alnylam Pharmaceuticals prices public offering of common stock

* Alnylam Pharmaceuticals prices public offering of common stock

May 24 2017

BRIEF-Alnylam Pharmaceuticals reports proposed public offering of common stock

* Alnylam Pharmaceuticals announces proposed public offering of common stock

May 23 2017

Earnings vs. Estimates